Molecular Partners (MOLN) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Molecular Partners (MOLN) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 2.7% versus a loss of 49.3%. Over five years, TLSA leads with a -27.2% price change compared with -80.8% for MOLN. Molecular Partners is the larger company by market cap ($145.9 million vs $141.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | TLSA |
|---|---|---|
| Share price | $3.81 | $1.11 |
| Market cap | $145.94M | $141.26M |
| 1-day change | 0.00% | +0.91% |
| YTD return | -12.59% | -26.17% |
| 1-year return | +2.70% | -49.31% |
| 5-year return | -80.76% | -27.15% |
| EPS (TTM) | $-1.71 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.36 | $2.30 |
| 52-week low | $3.53 | $0.76 |
| Distance from 52-week high | -28.92% | -51.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +172.18% | +618.92% |
| Average volume | 1.18K | 717.23K |
| Shares outstanding | 38.31M | 127.26M |
| Employees | 134 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed TLSA by 52.0 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
MOLN vs TLSA FAQ
Which is bigger, Molecular Partners or Tiziana Life Sciences?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $141.26M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, MOLN or TLSA?
MOLN returned +2.70% over the past 12 months, compared with -49.31% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Tiziana Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Molecular Partners and Biotechnology: Pharmaceutical Preparations for Tiziana Life Sciences.